Unity Biotechnology, Inc. (UNBX)
OTCMKTS · Delayed Price · Currency is USD
0.0550
-0.0487 (-46.96%)
At close: Aug 1, 2025

Unity Biotechnology Company Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging.

Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.

The company also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, an α-Klotho hormone drug candidate for multiple neurology indications.

The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015.

Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Unity Biotechnology, Inc.
CountryUnited States
Founded2009
IndustryBiotechnology
SectorHealthcare
Employees16

Contact Details

Address:
285 East Grand Avenue
South San Francisco, Delaware 94080
United States
Phone650 416 1192
Websiteunitybiotechnology.com

Stock Details

Ticker SymbolUNBX
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS91381U2006
SIC Code2836

Key Executives

NamePosition
Lynne Marie Sullivan CPAChief Financial Officer and Head of Corporate Development
Alexander Hieu Nguyen J.D.Chief Legal Officer and Head of Operations
Dr. Jan M. van Deursen Ph.D.Founder
Dr. Przemyslaw Sapieha Ph.D.Chief Scientist
Alicia Tozier M.B.A.Chief Strategy Officer
Dr. Federico Grossi M.D., Ph.D.Chief Medical Officer